ZOVIRAX TAB 200MG TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ACYCLOVIR

から入手可能:

GLAXOSMITHKLINE INC

ATCコード:

J05AB01

INN（国際名）:

ACYCLOVIR

投薬量:

200MG

医薬品形態:

TABLET

構図:

ACYCLOVIR 200MG

投与経路:

ORAL

パッケージ内のユニット:

100

処方タイプ:

Prescription

治療領域:

NUCLEOSIDES AND NUCLEOTIDES

製品概要:

Active ingredient group (AIG) number: 0115506002; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2016-01-11

製品の特徴

_2014-11-10/131-pristine-pm-zovirax.doc _
_ _
_ _
_ _
_ _
_Page 1 of 38_
PRODUCT MONOGRAPH
PR
ZOVIRAX
®
Acyclovir Oral Suspension USP, 200 mg /5 mL
Acyclovir Tablets USP, 200 mg
Antiviral Agent
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Revision:
November 10, 2014
Submission Control No: 177766
_©_
_2014 GlaxoSmithKline Inc. All Rights Reserved _
_ZOVIRAX is a registered trademark of GlaxoSmithKline Inc. _
_2014-11-10/131-pristine-pm-zovirax.doc _
_ _
_ _
_ _
_ _
_Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFORMATION
..........................................................